Letter Re: Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.
作者信息
Zhu W, Wei Z, Xie R
机构信息
The Second Clinical Medical College, Lanzhou University, Gansu, China.
Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China.
出版信息
ESMO Open. 2025 Jun;10(6):105313. doi: 10.1016/j.esmoop.2025.105313. Epub 2025 Jun 3.
Abstract
摘要
相似文献
1
Letter Re: Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.
ESMO Open. 2025 Jun;10(6):105313. doi: 10.1016/j.esmoop.2025.105313. Epub 2025 Jun 3.
2
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.
ESMO Open. 2025 Mar;10(3):104297. doi: 10.1016/j.esmoop.2025.104297. Epub 2025 Feb 21.
3
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae360.
4
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Future Oncol. 2021 Aug;17(24):3151-3162. doi: 10.2217/fon-2021-0202. Epub 2021 May 17.
5
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
Future Oncol. 2021 May;17(15):1923-1931. doi: 10.2217/fon-2020-1215. Epub 2021 Feb 10.
6
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
Adv Ther. 2020 Nov;37(11):4585-4598. doi: 10.1007/s12325-020-01477-w. Epub 2020 Sep 8.
7
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15.
8
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.
Onco Targets Ther. 2021 Aug 11;14:4439-4450. doi: 10.2147/OTT.S307273. eCollection 2021.
9
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer.
J Clin Pharmacol. 2025 Jul;65(7):873-884. doi: 10.1002/jcph.70001. Epub 2025 Feb 19.
10
Comparing fruquintinib with placebo for treating patients with previously treated metastatic colorectal cancer: a plain language summary of the FRESCO-2 study.
Future Oncol. 2025 Feb;21(3):281-292. doi: 10.1080/14796694.2024.2425568. Epub 2024 Nov 29.
本文引用的文献
1
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.
ESMO Open. 2025 Mar;10(3):104297. doi: 10.1016/j.esmoop.2025.104297. Epub 2025 Feb 21.
2
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
Future Oncol. 2021 May;17(15):1923-1931. doi: 10.2217/fon-2020-1215. Epub 2021 Feb 10.
3
The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy.
Cancer Manag Res. 2018 Aug 29;10:3015-3021. doi: 10.2147/CMAR.S166468. eCollection 2018.
4
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.
ESMO Open. 2017 Nov 23;2(5):e000284. doi: 10.1136/esmoopen-2017-000284. eCollection 2017.
Zotero 插件